Read our latest updates & insights

On 17 March 2026, Celltrion announced that the subcutaneous (SC) formulation of Avtozma®, biosimilar to Roche’s Actemra® (tocilizumab), is now available in the US.  The SC formulation is approved for rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopat...

On 16 March 2026, Samsung Bioepis and its sister company, Epis NexLab, announced they have entered into a research collaboration and licence agreement with G2GBIO to develop long-acting semaglutide.  G2GBIO specialises in the development of sustained-release formulations us...

On 13 March 2026, Novartis received FDA approval for Cosentyx® (secukinumab) for the treatment of moderate to severe Hidradenitis Suppurativa (HS) in paediatric patients aged 12 years and older.  According to Novartis, Cosentyx® is the only IL-17A inhibitor approved for thi...

On 13 March 2026, IAM reported that Regeneron has applied to a US Court to seek discovery of manufacturing-related documents from Sam Chun Dang’s (SCD’s) US subsidiaries for use in its patent infringement litigation in Taiwan regarding SCD’s biosimilar to Regeneron’s Eylea®...

On 13 March 2026, Sandoz filed an appeal with the US Court of Appeals for the Fourth Circuit, challenging the dismissal of the antitrust proceeding it had commenced in April 2025 alleging that Amgen “unlawfully extended and entrenched its monopoly” for Enbrel® by “blocking ...

On 12 March 2026, Juve Patent reported that Sanofi/Regeneron and Amgen “have apparently settled” their dispute over PCSK9 inhibitors Praluent® (arilocumab) and Repatha® (evolocumab).  No announcements have been made by the companies and there are no details available regard...

On 11 March 2026, Celltrion announced the European launch of its Remsima® IV liquid formulation, biosimilar to Janssen’s Remicade® (infliximab).  This follows the November 2025 approval of Remsima® IV liquid formulation by the European Commission for the treatment of rheuma...